Use of DNA methyltransferase inhibitor and poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) in the treatment of PARPi-resistant, high-grade serous ovarian cancer

被引：0
作者：
Shafa, Anousheh [1 ]
Hou, Xiaonan [1 ]
Wang, Liewei [1 ]
Weroha, S. John [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
GYNECOLOGIC ONCOLOGY | 2024年 / 190卷
关键词：
D O I：
10.1016/j.ygyno.2024.07.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1275
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [31] COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS (PARPI) IN THE MAINTENANCE TREATMENT OF ADVANCED OVARIAN CANCER
    Hettle, R.
    McLaurin, K.
    Mihai, A.
    Poeton, A.
    Muston, D.
    Lopez-Acevedo, M.
    Maguire, P.
    Wynne, T.
    VALUE IN HEALTH, 2020, 23 : S42 - S42
  • [32] Kombinationstherapie mit Inhibitoren der Poly(Adenosindiphosphat-Ribose)-Polymerasen (PARPi) und des Androgenrezeptorsignalweges (ARPi) beim metastasierten kastrationsrefraktären ProstatakarzinomCombination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer
    Marc-Oliver Grimm
    Susan Foller
    Katharina Leucht
    Die Urologie, 2023, 62 (12) : 1269 - 1280
  • [33] Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418).
    Chiou, Victoria L.
    Kohn, Elise C.
    Annunziata, Christina M.
    Minasian, Lori M.
    Lipkowitz, Stan
    Yu, Minshu
    Gordon, Nicolas
    Houston, Nicole D.
    Lee, Jung-min
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer (vol 13, 3334, 2023)
    Sauriol, Skye Alexandre
    Carmona, Euridice
    Udaskin, Molly L.
    Radulovich, Nikolina
    Leclerc-Desaulniers, Kim
    Rottapel, Robert
    Oza, Amit M.
    Lheureux, Stephanie
    Provencher, Diane M.
    Mes-Masson, Anne-Marie
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [35] Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer
    Shim, Jung-In
    Ryu, Ji-Yoon
    Jeong, Soo Young
    Cho, Young-Jae
    Choi, Jung-Joo
    Hwang, Jae Ryoung
    Choi, Ju-Yeon
    Sa, Jason K.
    Lee, Jeong-Won
    GYNECOLOGIC ONCOLOGY, 2022, 165 (02) : 270 - 280
  • [36] Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study
    Ang, Joo Ern
    Gourley, Charlie
    High, Hilda Anne
    Shapira-Frommer, Ronnie
    Powell, C. Bethan
    Castonguay, Vincent
    De Greve, Jacques
    Yap, Timothy Anthony
    Fong, Peter C. C.
    Olmos, David
    Banerjee, Susana N.
    Chen, Lee-may
    Friedlander, Michael
    Kaufman, Bella
    Oza, Amit M.
    De Bono, Johann Sebastian
    Gore, Martin Eric
    Kaye, Stanley B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
    Matulonis, Ursula A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Spencer, Stuart
    Parry, David
    Grinsted, Lynda
    Ledermann, Jonathan A.
    CANCER, 2016, 122 (12) : 1844 - 1852
  • [38] Novel combination therapy of DNA methyltransferase inhibitor guadecitabine (SGI-110) and PARP inhibitor talazoparib (BMN-673) for BRCA-proficient high-grade serous ovarian cancer
    Pulliam, Nicholas
    Taverna, Pietro
    Lyons, John
    Nephew, Kenneth P.
    CANCER RESEARCH, 2017, 77
  • [39] Proteomic landscaping of high-grade serous ovarian carcinoma identifies stearoyl-CoA desaturase 5 as a potential predictive biomarker for poly(ADP-ribose) polymerase inhibitor response
    Kim, Se Ik
    Kim, Hyeyoon
    Dan, Kisoon
    Park, Hong-Beom
    Lee, Cheol
    Kim, Hee Seung
    Chung, Hyun Hoon
    Kim, Jae-Weon
    Park, Noh Hyun
    Han, Dohyun
    Lee, Maria
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (05):
  • [40] Patient-reported quality of life during PARP-inhibitor treatment for high-grade serous ovarian cancer
    Philp, Lauren
    Eisenhauer, Eric
    Bregar, Amy
    del Carmen, Marcela
    Goodman, Annekathryn
    Randall, Thomas
    Mazina, Varvara
    Hubbell, Harrison
    Sisodia, Rachel
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S232 - S232
12345